LPCN 1021

DRUG3 trials

Sponsors

Lipocine Inc.

Conditions

Hypogonadism, Male

Phase 3

Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).

CompletedNCT03242590

Lipocine Inc.Hypogonadism, Male

Start: 2016-12-31End: 2017-07-31Updated: 2019-10-23

Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)

CompletedNCT03242408

Lipocine Inc.Hypogonadism, Male

Start: 2017-01-31End: 2017-07-31Updated: 2019-10-23

Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men

CompletedNCT03868059

Lipocine Inc.Hypogonadism, Male

Start: 2018-04-30End: 2019-02-21Updated: 2021-06-10

Related Papers

Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism

Andrology2024-09-103 citations

(393) Pooled Safety Analysis of Ten Clinical Studies Evaluating Fixed-Dose Oral Testosterone Undecanoate in Male Patients With Testosterone Deficiency

The Journal of Sexual Medicine2023-05-01

A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism

Andrology2022-01-0717 citations

MP36-04 CLINICAL EXPERIENCE WITH TLANDO IN HYPOGONADAL MEN

The Journal of Urology2021-08-04

Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men.

2021-06-3017 citations

Efficacy and Safety of TLANDO, A Novel Oral Easy to Prescribe and Use TRT Option

Journal of the Endocrine Society2021-05-012 citations

Low Testosterone in Males May Warrant Liver Health Assessment and Intervention

Journal of the Endocrine Society2021-05-01

SAT-052 A Novel Oral Testosterone Therapy (TLANDO) Safely Restores Testosterone to Eugonadal Levels with Fixed Dose Treatment

Journal of the Endocrine Society2020-04-013 citations

316 Paradigm Shifting Beneficial Effects of TLANDO (Oral Testosterone) on Liver

The Journal of Sexual Medicine2020-01-01